Evotec Investor Day Presentation Deck
evotec
Padlock
THERAPEUTICS
IDD in
Autoimmunity
Initiated 2014
Acquired by BMS¹)
TESARO
IDD in Oncology
Initiated 2016
PAGE 75
Acquired by GSK 5)
FIBROCOR
IDD in Fibrosis
Initiated 2017
Partnered with
Galapagos 20192)
disarm
THERAPEUTICS
IDD in CNS
Initiated in 2019
Acquired by Lilly6)
R&D Autobahn creates much better exit points for our partners
Selected examples of impact and value inflection
Aeovian
PHARMACEUTICALS
IDD & INDIGO in
Rare & Age
Related
Initiated 2017
PDC Milestone
20183)
enterprise
THERAPEUTICS
IDD in Respiratory
Initiated in 2018
Project acquired by
Roche7)
FORGE
Therapeutics
IDD & DEV in
Infectious Dis.
Initiated 2016
Partnership with
Roche 20204)
Multiple others
in stealth mode...
Pain, Oncology,
ID, Metabolic, etc.
¹) https://lifescivc.com/2016/03/bms-secures-keys-padlock/
2) https://www.evotec.com/en/innovate/spin-offs-and-other-holdings/fibrocor-therapeutics
3)
4) https://forgetherapeutics.com/forge-enters-into-collaboration-with-roche-to-develop-novel-sntibiotic-to-treat-lung-infections/
"With Padlock, we decided to do something different -
and signed up for a single, large collaboration with
Evotec, where they would cover all of our research. They
were essentially our entire discovery execution team. It's
obviously worked well ... It also simplified the operating
model enormously.
"We are extremely glad about the fast progress of our
programme which has been made possible by Evotec's
expertise and technical excellence. The successful
identification and de-risking of our lead clinical candidate
was instrumental in the closing of our Series A financing.
Stelios T. Tzannis, PhD, President & CEO of Aeovian
https://www.evotec.com/en/invest/news--announcements/press-releases/p/evotec-reaches-milestone-in-integrated-drug-discovery-and-development-partnership-with-aeovian-5851
Bruce Booth, Partner Atlas Ventures
5) https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-tesaro-an-oncology-focused-biopharmaceutical-company/
6) https://www.bloomberg.com/press-releases/2020-10-15/lilly-announces-agreement-to-acquire-disarm-therapeutics
7) https://enterprisetherapeutics.com/enterprise-therapeutics-first-in-class-tmem16a-potentiator-program-for-treatment-of-cystic-fibrosis-and-other-
respiratory-diseases-acquired-by-roche/View entire presentation